Liver cancer roadmap links tumor hallmarks to treatment, including targetable mutations

MedicalXpress | avr. 16, 2026

A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the clearest roadmaps to date for understanding and treating liver cancer, one of the deadliest cancers worldwide. Published in Cell, the study, "Hallmarks of Liver Cancer: Therapeutic Implications", applies the widely used "Hallmarks of Cancer" framework to liver tumors, linking the biology of the disease to treatment strategies, including immunotherapy and precision medicine approaches, particularly in the approximately 45% of bile duct cancers that harbor targetable mutations.